Jason Christiansen

Ab-ilityTM is very relevant due diligence for any antibody asset transactions and supply chain planning. I wouldn't buy a house without a survey, I wouldn't acquire an antibody without Ab-ilityTM.

11

Nice review on P53 https://lnkd.in/g8hmefQY

10

Folks, xBiologix is heading to #BIO2024 to connect solid phase tumor profiling with translational research & preclinical drug development. Join us in San Diego and learn how a simplified single staining step & multiplexed immunofluorescence makes profiling the required number of biomarkers available to virtually any research scientist or pathologist. #spatialbiology #multiplexIF

14

DRAGEN V4.3…making huge strides with difficult genes. New specialized callers enable genotyping of genes such as PMS2, NEB, IKBKG etc. in segmental duplication regions

20

Bio-Blocks allow cells to create the micro-environments they want. Better cells and better biologics. Want more info or to set up a 1x1 with a specialist? Email us at info@ronawk.com to set up a meeting. #cellculture, #tissueengineering

16

If you haven’t thought about Single cell/spatial/insitu workflows from 10x Genomics , it’s never too late to start. With 5 new products launched and that only being that only bring the start of it, how far are you going to push your biological questions! Have questions or want to get started ? Drop us a line to see how we can help you start your journey today! #singlecell #spatialbiology #insitu

8

Next step for CAR T cell therapy: in vivo CART from @ASGCT24 Interius Biotherapeutics will release preclinical study of INT2104 (CAR20) in humanized NSG-Tg (Hu-IL15) and Cyno. INT2104 utilizes a lentiviral vector platform that incorporates CD7-targeting to specifically transduce T cells and NK cells upon intravenous (i.v.) administration.

18

🌟 Exciting Learning Opportunity for Chemists and Researchers! 🌟 Join us for an enlightening webinar titled "Enhancing Synthesis Workflows Through Computer-Assisted Retrosynthesis," hosted by SelectScience and featuring Dr. Ewa Gajewska, Head of Product Management for SYNTHIA™ Retrosynthesis Software at Merck. 📅 Date: June 21, 2024 ⏰ Time: 17:00 CET 🔗 Registration: https://lnkd.in/dWwBxK9W Why Attend? • Discover the Power of SYNTHIA™: Learn how SYNTHIA™ leverages advanced algorithms and chemical databases to transform drug discovery and chemical development processes. • Customize Your Workflow: Gain insights on customizing search parameters within SYNTHIA™ to optimize synthetic routes, reducing manual efforts and accelerating outcomes. • Address Synthetic Challenges: Understand the common challenges in synthetic chemistry and how SYNTHIA™ addresses them, paving the way for future advancements. This webinar is a must-attend for: • Drug Discovery Chemists • Cheminformaticians • Medicinal Chemists • Process Chemists • Organic Chemists Participants will also have the opportunity to request a certificate of attendance for continuing education purposes. Don’t miss out on this chance to enhance your knowledge and skills in drug discovery and synthetic chemistry. Secure your spot today! #Chemistry #DrugDiscovery #Webinar #SYNTHIA #SelectScience #Education #ProfessionalDevelopment #TeamMerck

3

1 Comment

Let’s talk flow - A flow cytometry monthly virtual meetup Our monthly meetup is fast approaching! 🧪 Join us for Part-II of our series on "Fluorophores: Bright is not always better." Building on last month's discussion where we tackled the fundamentals of assigning fluorophores by delving into concepts like brightness and antigen density, this session dives deeper into overcoming issues with spread in your panel. If you've encountered challenges in resolving populations due to spread, this session promises to be a game-changer. Don't miss out on the opportunity to learn how to optimize your data and elevate your research to new heights. Mark your calendars and get ready to transform your approach to panel design! 🧬 🗓️ Save the Date: Wednesday, June 26, 2024 🔗 Register Now - We are offering two sessions for your convenience: ⏰ 1st - 10AM CET / 1:30PM IST / 6PM AEST: https://lnkd.in/gBARWtjx ⏰ 2nd - 10 AM PST / 1 PM EST / 2PM BRT: https://lnkd.in/g9JCx5XA 🔍Quick preview - Here are 3 points to consider for minimizing the effect of spread in your panel: 1️⃣ Spreading is an effect inherent to flow cytometry and cannot be corrected with compensation. 2️⃣ Using fluorophores like NovaFluor dyes with low cross-laser excitation reduces spillover/spread. 3️⃣ The brighter the fluorophore, the more spreading will be introduced to the panel. Join us for an engaging discussion on spreading effect and gain valuable insights from industry experts. 🌟 We can't wait to see you there! #FlowCytometry #PanelDesign #LetsTalkFlow #Immunology

16

NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development - https://lnkd.in/gJU2SHAH NMDP BioTherapies℠ formerly Be The Match BioTherapies, a leader in cell and gene therapy development support, unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings. The strategic enhancements to its suite are designed to address the evolving needs of the allogeneic cell therapy industry, emphasizing optimized delivery times, customizable options, and expanded capabilities. “We have leveraged over three decades of experience in managing cellular product collections, working closely with cell and gene therapy developers to deliver an advanced allogeneic suite of compliant products,” said Tom Hochuli, President of NMDP BioTherapies. Read more at: https://lnkd.in/gJU2SHAH #cellandgenetherapy #stemcell #celltherapy

7

How can you overcome your antibody-drug conjugate (ADC) solubility challenges? ChetoSensar™ solubilization technology is the answer! The conjugation of hydrophobic payloads to an antibody will often result in a hydrophobic #ADC prone to aggregation. ChetoSensar™ is a chito-oligosaccharide that can be incorporated into the linker region alongside hydrophobic payloads to increase solubility, enabling the further pursuit of your #payload of choice. This technology offers a great deal of flexibility, is compatible with a variety of payloads and linkers and has demonstrated increased ADC efficacy. Want to learn more on how to solve ADC solubility challenges? Read this article

4

🌟Spotlight on Orion🌟 Data in hours. Validation in days. Studies in weeks. Discover whole-slide precision spatial biology with Orion. Orion enables rapid, sub-cellular resolution scanning and analysis of patient biopsies for up to 20 biomarkers, with turnaround times to support large cohort studies and to inform patient responsiveness in immune therapy trials. Explore the Orion Platform, https://lnkd.in/g_FvDCG. #SpatialBiology #Biomarkers #RareCyte

32

1 Comment

'Adenosine deaminases that act on RNA, then and now' In this article from the #RNASpecialIssue, Brenda L. Bass from the Department of Biochemistry, University of Utah, recounts key experiments that led to her entry into the RNA editing/modification field. It highlights initial observations made by pioneers in the ADAR field, and how they fit into our current understanding of this family of enzymes. http://bit.ly/4baKfOC #RNAEpitranscriptomics #inosine #dsRNA

7

Study of #mRNA translation which showed GC3, percentage of G or C at the third codon, is the best predictor of SHBLE protein translation efficiency. The individual explanatory power from CUPrefs, TpA or CpG frequency, and mRNA folding energy was not as strong. It also demonstrated that the ORF located downstream in a bicistronic mRNA can be translated by human cells, albeit at much lower levels than the upstream ORF. https://lnkd.in/ef36XJwn

38

If you're looking to expand your knowledge on working with FFPE tissue for #nucleicacid analysis check out "Successfully Overcoming the Challenges of Working with FFPE Samples," where @martyenseberger from Promega Corporation expertly summarizes the best practices for working with FFPE. #genomic #transcriptomic #FFPE

20

Meet ZT Scan DIA: The game-changer in quantitative proteomics 📢📢📢 Scientists in biomarker research often face a tough choice: focus on a few proteins with high sensitivity or cover many with less precision. ZT Scan DIA changes the game by offering both data depth and measurement quality. ➡️ Exceptional speed and sensitivity. ➡️ Precise quantitation of entire proteomes. Say goodbye to compromises and hello to actionable data in large-scale clinical research and small sample studies. #Proteomics #BiomarkerResearch #ZTScanDIA #QuantitativeAnalysis #MassSpec

7

Traditional WES is a valuable tool, but its focus on exome regions can miss key variants. At 3billion, we're pushing the boundaries with our Enhanced Exome technology. This innovative approach goes beyond the exome, enabling detection of variants in: Non-coding regions, Mitochondrial genes and CNV. By incorporating these often-overlooked areas, Enhanced Exome empowers 3billion to deliver a more comprehensive WES-based test for rare diseases. This translates to higher diagnostic rates and improved outcomes for patients.

17

A novel dual-plasmid platform provides scalable transfection yielding improved productivity and packaging across multiple AAV serotypes and genomes Transient transfection of mammalian cells using plasmid DNA is a standard method to produce adeno-associated virus (AAV) vectors allowing for flexible and scalable manufacture. Typi- cally, three plasmids are used to encode the necessary compo- nents to facilitate vector production; however, a dual-plasmid system, termed pDG, was introduced over 2 decades ago demonstrating two components could be combined resulting in comparable productivity to triple transfection. We have developed a novel dual-plasmid system, pOXB, with an alterna- tive arrangement of sequences that results in significantly increased AAV vector productivity and percentage of full cap- sids packaged in comparison to the pDG dual design and triple transfection. Here, we demonstrate the reproducibility of these findings across seven recombinant AAV genomes and multiple capsid serotypes as well as the scalability of the pOXB dual- plasmid transfection at 50-L bioreactor scale. Purified drug substance showed a consistent product quality profile in line with triple-transfected vectors, except for a substantial improvement in intact genomes packaged using the pOXB dual- transfection system. Furthermore, pOXB dual- and tri- ple-transfection-based vectors performed consistently in vivo. The pOXB dual plasmid represents an innovation in AAV manufacturing resulting in significant process gains while maintaining the flexibility of a transient transfection platform. https://lnkd.in/ew_5QxxR

64